Onco Therapies, a subsidiary of Strides Arcolab, has received US Food and Drug Administration (FDA) approvals for anti-cancer Cisplatin injection.
The company's shares on the BSE rose slightly over 3 per cent to close at Rs 653 a share following the announcement.
Cisplatin is a chemotherapy drug and is used to treat various types of cancers, including sarcomas, some carcinomas (example small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumours. The company in a release said approvals is for Cisplatin injection of one mg/ml packages in 50 ml and 100 ml multiple dose vials.
It is amongst the products in the drug shortage list of USFDA. According to the IMS data, the US market for generic Cisplatin is about $10 million.